Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
KIN's Cash to Debt is ranked higher than
71% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. KIN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KIN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Interest Coverage No Debt
KIN's Interest Coverage is ranked lower than
57% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KIN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 12.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -29.46
KIN's ROE (%) is ranked higher than
51% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. KIN: -29.46 )
Ranked among companies with meaningful ROE (%) only.
KIN' s ROE (%) Range Over the Past 10 Years
Min: -33.44  Med: -23.38 Max: -13.32
Current: -29.46
-33.44
-13.32
ROA (%) -28.64
KIN's ROA (%) is ranked lower than
51% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. KIN: -28.64 )
Ranked among companies with meaningful ROA (%) only.
KIN' s ROA (%) Range Over the Past 10 Years
Min: -32.42  Med: -22.65 Max: -12.87
Current: -28.64
-32.42
-12.87
ROC (Joel Greenblatt) (%) -6960.18
KIN's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. KIN: -6960.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KIN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -70316.67  Med: -41865.97 Max: -13415.27
Current: -6960.18
-70316.67
-13415.27
» KIN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

KIN Guru Trades in Q1 2015

Jim Simons 114,700 sh (+462.25%)
John Rogers 283,600 sh (+110.97%)
Seth Klarman 3,013,848 sh (unchged)
» More
Q2 2015

KIN Guru Trades in Q2 2015

John Rogers 1,212,359 sh (+327.49%)
Jim Simons 177,855 sh (+55.06%)
Seth Klarman 3,013,848 sh (unchged)
» More
Q3 2015

KIN Guru Trades in Q3 2015

John Rogers 1,750,224 sh (+44.37%)
Seth Klarman 3,013,848 sh (unchged)
Jim Simons 119,810 sh (-32.64%)
» More
2015

KIN Guru Trades in 2015

John Rogers 2,551,234 sh (+45.77%)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Kindred Biosciences Inc

Guru John Rogers Raises Stake in Helping Animals Rogers ups stake in Kindred Biosciences by 45%
Guru John Rogers (Trades, Portfolio) is the founder of Ariel Investments, which is located in Chicago. It specializes in small and mid-cap stocks based in the U.S. Read more...

Ratios

vs
industry
vs
history
P/B 0.80
KIN's P/B is ranked higher than
92% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 2.68 vs. KIN: 0.80 )
Ranked among companies with meaningful P/B only.
KIN' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 5.6
Current: 0.8
0
5.6
EV-to-EBIT 0.61
KIN's EV-to-EBIT is ranked higher than
91% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 19.07 vs. KIN: 0.61 )
Ranked among companies with meaningful EV-to-EBIT only.
KIN' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.62
Current: 0.61
0
0.62
EV-to-EBITDA 0.61
KIN's EV-to-EBITDA is ranked higher than
92% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 17.41 vs. KIN: 0.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
KIN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.62
Current: 0.61
0
0.62
Current Ratio 28.27
KIN's Current Ratio is ranked higher than
94% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. KIN: 28.27 )
Ranked among companies with meaningful Current Ratio only.
KIN' s Current Ratio Range Over the Past 10 Years
Min: 10.63  Med: 30.74 Max: 45.03
Current: 28.27
10.63
45.03
Quick Ratio 28.27
KIN's Quick Ratio is ranked higher than
94% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. KIN: 28.27 )
Ranked among companies with meaningful Quick Ratio only.
KIN' s Quick Ratio Range Over the Past 10 Years
Min: 10.63  Med: 30.74 Max: 45.03
Current: 28.27
10.63
45.03

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.83
KIN's Price/Net Cash is ranked higher than
96% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: 6.04 vs. KIN: 0.83 )
Ranked among companies with meaningful Price/Net Cash only.
KIN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.28  Med: 1.65 Max: 5.19
Current: 0.83
1.28
5.19
Price/Net Current Asset Value 0.83
KIN's Price/Net Current Asset Value is ranked higher than
96% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: 6.40 vs. KIN: 0.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KIN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.27  Med: 1.65 Max: 5.15
Current: 0.83
1.27
5.15
Price/Tangible Book 0.82
KIN's Price/Tangible Book is ranked higher than
95% of the 1048 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. KIN: 0.82 )
Ranked among companies with meaningful Price/Tangible Book only.
KIN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 1.64 Max: 5.15
Current: 0.82
1.26
5.15
Earnings Yield (Greenblatt) (%) 168.28
KIN's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. KIN: 168.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KIN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1723.02  Med: 0.00 Max: 934.82
Current: 168.28
-1723.02
934.82

More Statistics

EPS $ -1.39
Short Percentage of Float1.43%
52-Week Range $2.90 - 7.91
Shares Outstanding(Mil)19.81

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 1 9 56
EPS($) -1.54 -1.80 -1.60 -0.75
EPS without NRI($) -1.54 -1.80 -1.60 -0.75

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:17K.Germany,
» More Articles for KIN

Headlines

Articles On GuruFocus.com
Guru John Rogers Raises Stake in Helping Animals Dec 16 2015 
Seth Klarman Nearly Doubles Stake in Atara Biotherapeutics Apr 15 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 

More From Other Websites
Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of... Jan 26 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Jan 11 2016
Kindred Biosciences to Provide Corporate Update Jan 07 2016
Kindred Biosciences Submits KIND-012 New Animal Drug Application Technical Section for Chemistry,... Dec 17 2015
Guru John Rogers Raises Stake in Helping Animals Dec 16 2015
As Calendar Year Dwindles, So Does Logic Dec 10 2015
KINDRED BIOSCIENCES, INC. Financials Dec 08 2015
A Look Inside the Chart, Technical Insights - Research on Westbury Bancorp, FalconStor Software,... Dec 03 2015
Is Kindred Biosciences Inc (KIN) Going to Burn These Hedge Funds? Dec 02 2015
What Do Hedge Funds Think of FinTech Acquisition Corp. (FNTCU)? Nov 27 2015
Is Ocean Shore Holding Co (OSHC) A Good Stock To Buy? Nov 23 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Other Events Nov 16 2015
Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses,... Nov 16 2015
Kindred Bio reports 3Q loss Nov 09 2015
Kindred Bio reports 3Q loss Nov 09 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 09 2015
Kindred Biosciences Announces Third Quarter 2015 Financial Results Nov 09 2015
Kindred Biosciences (KIN) Is in Oversold Territory: What's Next? Oct 01 2015
Can Kindred Biosciences (KIN) Keep the Earnings Streak Alive This Quarter? Sep 14 2015
Kindred Bio reports 2Q loss Aug 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK